{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:47:36Z","timestamp":1772923656947,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this retrospective study was to investigate the impact of a broad spectrum of antihypertensive (AH) medications on urinary tract infections (UTI) of outpatients diagnosed in general practices in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included a total of 367,960 patients aged\u2009\u2265\u200918\u00a0years newly a diagnosed with UTI in 1274 general practices in Germany between January 2010 and December 2019. The analysis was conducted for five groups representing five AH therapy classes (diuretics (DIU); beta blockers (BB); calcium channel blockers (CCB); ACE inhibitors (ACEi); angiotensin II receptor blockers (ARB)), each containing 73,592 patients. A Cox regression model was used to analyze the association between each antihypertensive drug class and UTI incidence as compared to all other antihypertensive drug classes (as a group).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of UTI diagnosis was slightly higher in patients treated with DIU (8.6%), followed by ACEi (8.1%), ARB (7.9%), and CCB (6.5%). Antibiotic therapy for UTI was given in 5.6% of DIU and 4.3% of CCB patients. The incidence of UTI and antibiotic therapy was much higher in women than in men across all therapy classes. No significant increase or decrease in UTI incidence or antibiotic therapy was observed in any of the AH therapy classes investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present study did not identify a significant increase or decrease of UTI incidence or antibiotic therapy in patients treated with ACEi, ACB, CCB, beta blockers or diuretics. Across all AH classes studied, the incidence of UTI and antibiotic therapy was higher in women than in men, although not significantly.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-022-01895-8","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:25:52Z","timestamp":1659115552000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between antihypertensive medication and the risk of urinary tract infection (UTI) of outpatients: a retrospective cohort study"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-3646","authenticated-orcid":false,"given":"Niklas","family":"Gremke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kalder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18:785\u2013802. https:\/\/doi.org\/10.1038\/s41569-021-00559-8.","journal-title":"Nat Rev Cardiol"},{"key":"1895_CR2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","volume":"386","author":"MH Forouzanfar","year":"2015","unstructured":"Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2287\u2013323. https:\/\/doi.org\/10.1016\/S0140-6736(15)00128-2.","journal-title":"Lancet"},{"key":"1895_CR3","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, C\u00edfkov\u00e1 R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. https:\/\/doi.org\/10.1038\/nrdp.2018.14.","journal-title":"Nat Rev Dis Primers"},{"key":"1895_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s0092-8674(01)00241-0","volume":"104","author":"RP Lifton","year":"2001","unstructured":"Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545\u201356. https:\/\/doi.org\/10.1016\/s0092-8674(01)00241-0.","journal-title":"Cell"},{"key":"1895_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jash.2014.05.014","volume":"8","author":"LG Navar","year":"2014","unstructured":"Navar LG. Physiology: hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system. J Am Soc Hypertens. 2014;8:519\u201324. https:\/\/doi.org\/10.1016\/j.jash.2014.05.014.","journal-title":"J Am Soc Hypertens"},{"key":"1895_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72:537\u201348. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11065.","journal-title":"Hypertension"},{"key":"1895_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317\u201325. https:\/\/doi.org\/10.1016\/j.biopha.2017.07.091.","journal-title":"Biomed Pharmacother"},{"key":"1895_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nrendo.2015.6","volume":"11","author":"CA Romero","year":"2015","unstructured":"Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015;11:242\u201352. https:\/\/doi.org\/10.1038\/nrendo.2015.6.","journal-title":"Nat Rev Endocrinol"},{"key":"1895_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320. https:\/\/doi.org\/10.1001\/jama.2013.284427.","journal-title":"JAMA"},{"key":"1895_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jch.14216","volume":"23","author":"H Esam","year":"2021","unstructured":"Esam H, Kanukula R, Dhurjati R, Aerram R, Chevireddy S, Bhaumik S, et al. Systematic reviews of antihypertensive drugs: a review of publication trends, characteristics, and quality. J Clin Hypertens (Greenwich). 2021;23:915\u201322. https:\/\/doi.org\/10.1111\/jch.14216.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1895_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021;372:n189. https:\/\/doi.org\/10.1136\/bmj.n189.","journal-title":"BMJ"},{"key":"1895_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/CIRCRESAHA.118.313236","volume":"124","author":"A Benetos","year":"2019","unstructured":"Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124:1045\u201360. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313236.","journal-title":"Circ Res"},{"key":"1895_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/EDE.0000000000000088","volume":"25","author":"KB Pouwels","year":"2014","unstructured":"Pouwels KB, Bos JH, Hak E. ACE inhibitors and urinary tract infections. Epidemiology. 2014;25:466\u20137. https:\/\/doi.org\/10.1097\/EDE.0000000000000088.","journal-title":"Epidemiology"},{"key":"1895_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40264-013-0085-z","volume":"36","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Visser ST, Bos HJ, Hak E. Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis. Drug Saf. 2013;36:1079\u201386. https:\/\/doi.org\/10.1007\/s40264-013-0085-z.","journal-title":"Drug Saf"},{"key":"1895_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jac\/dks419","volume":"68","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Visser ST, Hak E. Effect of pravastatin and fosinopril on recurrent urinary tract infections. J Antimicrob Chemother. 2013;68:708\u201314. https:\/\/doi.org\/10.1093\/jac\/dks419.","journal-title":"J Antimicrob Chemother"},{"key":"1895_CR16","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.3399\/bjgp20X708173","volume":"70","author":"DM Lecky","year":"2020","unstructured":"Lecky DM, Howdle J, Butler CC, McNulty CA. Optimising management of UTIs in primary care: a qualitative study of patient and GP perspectives to inform the development of an evidence-based, shared decision-making resource. Br J Gen Pract. 2020;70:e330\u20138. https:\/\/doi.org\/10.3399\/bjgp20X708173.","journal-title":"Br J Gen Pract"},{"key":"1895_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","volume":"7","author":"B Foxman","year":"2010","unstructured":"Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653\u201360. https:\/\/doi.org\/10.1038\/nrurol.2010.190.","journal-title":"Nat Rev Urol"},{"key":"1895_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German disease analyzer database. Int J Clin Pharmacol Ther. 2018;56:459\u201366. https:\/\/doi.org\/10.5414\/CP203320.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1895_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5414\/CP203559","volume":"57","author":"A Warda","year":"2019","unstructured":"Warda A, Reese JP, Tanislav C, Kostev K. The association between antihypertensive therapy and the incidence of Parkinson\u2019s disease in patients followed in general practices in Germany. Int J Clin Pharmacol Ther. 2019;57:483\u20138. https:\/\/doi.org\/10.5414\/CP203559.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1895_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5414\/CP203088","volume":"56","author":"L Jacob","year":"2018","unstructured":"Jacob L, Kostev K. Persistence with antihypertensive drugs in patients with depression in Germany. Int J Clin Pharmacol Ther. 2018;56:162\u20138. https:\/\/doi.org\/10.5414\/CP203088.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1895_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5414\/CP204177","volume":"60","author":"J Heidemann","year":"2022","unstructured":"Heidemann J, Kalder M, Kostev K. Association between contraceptive use and risk of lower urinary tract infection (LUTI): a case-control study. Int J Clin Pharmacol Ther. 2022;60:167\u201375. https:\/\/doi.org\/10.5414\/CP204177.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1895_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107502","volume":"115","author":"J Heidemann","year":"2021","unstructured":"Heidemann J, Schmitz B, Kostev K. Association between antiseizure medication use and risk of urinary tract infection: a case-control study. Epilepsy Behav. 2021;115:107502. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107502.","journal-title":"Epilepsy Behav"},{"key":"1895_CR23","doi-asserted-by":"publisher","first-page":"175628721983217","DOI":"10.1177\/1756287219832172","volume":"11","author":"M Medina","year":"2019","unstructured":"Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172. https:\/\/doi.org\/10.1177\/1756287219832172.","journal-title":"Ther Adv Urol"},{"key":"1895_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s15010-007-6180-2","volume":"35","author":"KB Laupland","year":"2007","unstructured":"Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35:150\u20133. https:\/\/doi.org\/10.1007\/s15010-007-6180-2.","journal-title":"Infection"},{"key":"1895_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027221","volume":"9","author":"M Mulder","year":"2019","unstructured":"Mulder M, Baan E, Verbon A, Stricker B, Verhamme K. Trends of prescribing antimicrobial drugs for urinary tract infections in primary care in the Netherlands: a population-based cohort study. BMJ Open. 2019;9:e027221. https:\/\/doi.org\/10.1136\/bmjopen-2018-027221.","journal-title":"BMJ Open"},{"key":"1895_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051860","volume":"7","author":"MB Haeseker","year":"2012","unstructured":"Haeseker MB, Dukers-Muijrers NH, Hoebe CJ, Bruggeman CA, Cals JW, Verbon A. Trends in antibiotic prescribing in adults in Dutch general practice. PLoS ONE. 2012;7:e51860. https:\/\/doi.org\/10.1371\/journal.pone.0051860.","journal-title":"PLoS ONE"},{"key":"1895_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12913-016-1620-2","volume":"16","author":"M Fran\u00e7ois","year":"2016","unstructured":"Fran\u00e7ois M, Hanslik T, Dervaux B, Le Strat Y, Souty C, Vaux S, et al. The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey. BMC Health Serv Res. 2016;16:365. https:\/\/doi.org\/10.1186\/s12913-016-1620-2.","journal-title":"BMC Health Serv Res"},{"key":"1895_CR28","first-page":"1","volume":"13","author":"SM Schappert","year":"2006","unstructured":"Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001\u201302. Vital Health Stat. 2006;13:1\u201366.","journal-title":"Vital Health Stat"},{"key":"1895_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s1047-2797(00)00072-7","volume":"10","author":"B Foxman","year":"2000","unstructured":"Foxman B, Barlow R, D\u2019Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10:509\u201315. https:\/\/doi.org\/10.1016\/s1047-2797(00)00072-7.","journal-title":"Ann Epidemiol"},{"key":"1895_CR30","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Association CotKiCDatCfHBPRotAH. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985\u201391. https:\/\/doi.org\/10.1161\/hc4101.096153.","journal-title":"Circulation"},{"key":"1895_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.ejheart.2004.10.005","volume":"7","author":"T Juhlin","year":"2005","unstructured":"Juhlin T, Bj\u00f6rkman S, H\u00f6glund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail. 2005;7:1049\u201356. https:\/\/doi.org\/10.1016\/j.ejheart.2004.10.005.","journal-title":"Eur J Heart Fail"},{"issue":"(Suppl 2)","key":"1895_CR32","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1038\/sj.ejcn.1601902","volume":"57","author":"R Beetz","year":"2003","unstructured":"Beetz R. Mild dehydration: a risk factor of urinary tract infection? Eur J Clin Nutr. 2003;57(Suppl 2):S52\u20138. https:\/\/doi.org\/10.1038\/sj.ejcn.1601902.","journal-title":"Eur J Clin Nutr"},{"key":"1895_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3810\/pgm.2011.05.2291","volume":"123","author":"JL Meyers","year":"2011","unstructured":"Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133\u201343. https:\/\/doi.org\/10.3810\/pgm.2011.05.2291.","journal-title":"Postgrad Med"},{"key":"1895_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/pds.1501","volume":"17","author":"AE Akkerman","year":"2008","unstructured":"Akkerman AE, Kuyvenhoven MM, Verheij TJ, van Dijk L. Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates. Pharmacoepidemiol Drug Saf. 2008;17:378\u201383. https:\/\/doi.org\/10.1002\/pds.1501.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1895_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0002-9149(00)01042-0","volume":"86","author":"GF Diercks","year":"2000","unstructured":"Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijns HJ, et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol. 2000;86:635\u20138. https:\/\/doi.org\/10.1016\/s0002-9149(00)01042-0.","journal-title":"Am J Cardiol"},{"key":"1895_CR36","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"FW Asselbergs","year":"2004","unstructured":"Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809\u201316. https:\/\/doi.org\/10.1161\/01.CIR.0000146378.65439.7A.","journal-title":"Circulation"},{"key":"1895_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.kint.2018.06.029","volume":"94","author":"J Casper","year":"2018","unstructured":"Casper J, Schmitz J, Br\u00e4sen JH, Khalifa A, Schmidt BMW, Einecke G, et al. Renal transplant recipients receiving loop diuretic therapy have increased urinary tract infection rate and altered medullary macrophage polarization marker expression. Kidney Int. 2018;94:993\u20131001. https:\/\/doi.org\/10.1016\/j.kint.2018.06.029.","journal-title":"Kidney Int"},{"key":"1895_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/CLEP.S146757","volume":"10","author":"KE Mansfield","year":"2018","unstructured":"Mansfield KE, Douglas IJ, Nitsch D, Thomas SL, Smeeth L, Tomlinson LA. Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis. Clin Epidemiol. 2018;10:187\u2013202. https:\/\/doi.org\/10.2147\/CLEP.S146757.","journal-title":"Clin Epidemiol"},{"key":"1895_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5414\/cpp47617","volume":"47","author":"H Becher","year":"2009","unstructured":"Becher H, Kostev K, Schr\u00f6der-Bernhardi D. Validity and representativeness of the \u201cdisease analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47:617\u201326. https:\/\/doi.org\/10.5414\/cpp47617.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1895_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/pds.3823","volume":"24","author":"B Kowall","year":"2015","unstructured":"Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 2015;24:865\u201374. https:\/\/doi.org\/10.1002\/pds.3823.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1895_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.0000000000002791","volume":"87","author":"S Gollwitzer","year":"2016","unstructured":"Gollwitzer S, Kostev K, Hagge M, Lang J, Graf W, Hamer HM. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurology. 2016;87:466\u201372. https:\/\/doi.org\/10.1212\/WNL.0000000000002791.","journal-title":"Neurology"},{"key":"1895_CR42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/dom.12673","volume":"18","author":"W Rathmann","year":"2016","unstructured":"Rathmann W, Bongaerts B, Kostev K. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study. Diabetes Obes Metab. 2016;18:840\u20133. https:\/\/doi.org\/10.1111\/dom.12673.","journal-title":"Diabetes Obes Metab"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01895-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01895-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01895-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T10:16:07Z","timestamp":1679912167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01895-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01895-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"24 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The database used includes only anonymized data in compliance with the regulations of the applicable data protection laws. German law allows the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data.Because patients were only queried as aggregates and no protected health information was available for queries, no Institutional Review Board approval was required for the use of this database or the completion of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}